Guillain-Barré syndrome associated with SARS-CoV‑2 (analysis of clinical cases)
L. T. Akhmedzhanova,
V. V. Zakharov,
E. A. Drozdova,
S. A. Dzhukkaeva,
A. I. Isaikin,
O. N. Voskresenskaya,
Z. V. Surnina https://doi.org/10.33667/2078-531-2023-2-22-28
Abstract
COVID‑19 infection is associated with many neurological complications, one of which is acute autoimmune polyneuropathy or Guillain-Barré syndrome.
The aim of this study. To analyze clinical symptoms, electrophysiological parameters, and evaluate the efficacy of therapy for Guillain-Barré syndrome associated with SARS-CoV‑2 viral infection. The relationship between the severity of a previous COVID‑19 infection and the severity of damage to the peripheral nervous system was also studied. The article presents three clinical cases with different pathophysiological variants of the disease.
Methods of research. All patients underwent electroneuromyography, lumbar puncture, laboratory tests. In one case, the patient underwent confocal microscopy of the cornea to assess the condition of the corneal nerve fibers.
Conclusions. With timely diagnosis and treatment of Guillain-Barré syndrome associated with SARS-CoV‑2 virus, a good recovery of neurological disorders is observed, despite the severity of the viral infection itself
About the Authors
L. T. Akhmedzhanova
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Akhmedzhanova Luiza T., PhD Med, associate professor at Dept of Nervous Diseases and Neurosurgery, Institute of Clinical Medicine n. a. N. V. Sklifosovsky
Moscow
V. V. Zakharov
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Zakharov Vladimir V., DM Sci (habil.), professor at Dept of Nervous Diseases and Neurosurgery, Institute of Clinical Medicine n. a. N. V. Sklifosovsky
Moscow
E. A. Drozdova
City Hospital No. 13 of the Avtozavodsky District of Nizhny Novgorod
Russian Federation
Russian Federation
Drozdova Ekaterina A., PhD Med, neurologist, neuropsychologist-aphasiologist, head of Neurological Dept for Patients
Nizhny Novgorod
S. A. Dzhukkaeva
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Dzhukkaeva Sofya A., neurologist at University Clinical Hospital No. 3
Moscow
A. I. Isaikin
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Isaikin Alexei I., PhD Med, associate professor at Dept of Nervous Diseases and Neurosurgery, Institute of Clinical Medicine n. a. N. V. Sklifosovsky
Moscow
O. N. Voskresenskaya
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Moscow
Z. V. Surnina
Research Institute of Eye Diseases n. a. M. M. Krasnov
Russian Federation
Russian Federation
Surnina Zoya V., PhD Med, senior researcher at Dept of Pathology of the Optical Media of the Eye
Moscow
References
1. Sansone P, Giaccari LG, Aurilio C, et al. Post-Infectious Guillain-Barré Syndrome Related to SARS-CoV‑2 Infection: A Systematic Review. Life (Basel). 2021; 11 (2): 167. Published 2021 Feb 21. DOI: 10.3390/life11020167.
2. Jacobs BC, Rothbarth PH, Van der Meché FGA, et al. The spectrum of antecedent infections in Guillain-Barre’ syndrome: A case-control study Neurology. 1998; 51: 1110–1115. DOI: 10.1212/WNL.51.4.1110.
3. Parra B, Lizarazo J, Jiménez-Arango JA, et al. Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia. N Engl J Med. 2016; 375 (16): 1513–1523. DOI: 10.1056/NEJMoa1605564.
4. Kim JE, Heo JH, Kim HO, et al. Neurological complications during treatment of Middle East Respiratory Syndrome. J Clin Neurol. 2010; 13 (3): 227–233. DOI: 10.3988/jcn.2017.13.3.227.
5. Tsai LK, Hsieh ST, Chang YC. Neurological manifestations in severe acute respiratory syndrome. Acta Neurol Taiwan. 2005; 14 (3): 113–9. PMID: 16252612.
6. Finsterer, J., Scorza, F. A. Guillain-Barre syndrome in 220 patients with COVID‑19. Egypt J Neurol Psychiatry Neurosurg 57, 55 (2021). doi.org/10.1186/s41983–021–00310–7
7. Manganotti P, Pesavento V, Buoite Stella A. et al. Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV‑2. J Neurovirol. 2020; 26 (4): 605–606. DOI: 10.1007/s13365–020–00858–9.
8. Lantos JE, Strauss SB, Lin E. COVID‑19-associated Miller Fisher syndrome: MRI findings. AJNR Am J Neuroradiol. 2020; 41 (7): 1184–6. DOI: 10.3174/ajnr.A6609.
9. Andalib, S., Biller, J., Di Napoli, M. et al. Peripheral Nervous System Manifestations Associated with COVID‑19. Curr Neurol Neurosci Rep 21, 9 (2021). DOI: 10.1007/s11910–021–01102–5
10. Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain-Barré syndrome spectrum associated with COVID‑19: an up-to-date systematic review of 73 cases. J Neurol. 2021 Apr; 268 (4): 1133–1170. DOI: 10.1007/s00415–020–10124-x.
11. Dinkin M, Gao V, Kahan J, et al. COVID‑19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology. 2020 Aug 4; 95 (5): 221–223. DOI: 10.1212/WNL.0000000000009700.
12. Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID‑19. Neurology. 2020 Aug 4; 95 (5): e601–e605. DOI: 10.1212/WNL.0000000000009619.
13. Andalib, S., Biller, J., Di Napoli, M. et al. Peripheral Nervous System Manifestations Associated with COVID‑19. Curr Neurol Neurosci Rep 21, 9 (2021). DOI: 10.1007/s11910–021–01102–5.
14. Guadarrama-Ortiz, Parménides et al. Neurological Aspects of SARS-CoV‑2 Infection: Mechanisms and Manifestations. Frontiers in Neurology. Vol. 11. 1039. 4 Sep. 2020, DOI: 10.3389/fneur.2020.01039.
15. Mohammadi, Soheil et al. Understanding the Immunologic Characteristics of Neurologic Manifestations of SARS-CoV‑2 and Potential Immunological Mechanisms. Molecular Neurobiology. Vol. 57, 12 (2020): 5263–5275. DOI: 10.1007/s12035–020–02094-y.
16. Rabi, Firas A et al. SARS-CoV‑2 and Coronavirus Disease 2019: What We Know So Far. Pathogens (Basel, Switzerland). Vol. 9,3 231. 20 Mar. 2020, DOI: 10.3390/ pathogens9030231.
17. Meinhardt J, Radke J et al. Olfactory transmucosal SARS-CoV‑2 invasion as a port of central nervous system entry in individuals with COVID‑19. Nat Neurosci. 2021 Feb; 24 (2): 168–175. DOI: 10.1038/s41593–020–00758–5.
18. López-Collazo, Eduardo et al. Immune Response and COVID‑19: A mirror image of Sepsis. International Journal of Biological Sciences. Vol. 16, 14. 2479–2489. 9 Jul. 2020, DOI: 10.7150/ijbs.48400.
19. Keddie, Stephen et al. Epidemiological and cohort study finds no association between COVID‑19 and Guillain-Barré syndrome. Brain: A Journal of Neurology. Vol. 144,2 (2021): 682–693. DOI: 10.1093/brain/awaa433.
20. Freire M, Andrade A, Sopeña B, et al. Guillain Barré syndrome associated with COVID‑19- lessons learned about its pathogenesis during the first year of the pandemic, a systematic review. Autoimmun Rev. 2021; 20 (8): 102875. DOI: 10.1016/j.autrev.2021.102875.
21. Agosti E., Giorgianni, D’Amore F et al. Is Guillain-Barrè syndrome triggered by SARS-CoV‑2? Case report and literature review. Neurological Sciences.2021; 42: 607–612. DOI: 10.1007/s10072–020–04553–9.
22. Granger A, Omari M, Jakubowska-Sadowska K, et al. SARS-CoV‑2-Associated Guillain- Barre Syndrome with Good Response to Plasmapheresis. J Clin Neuromuscul Dis. 2020 Sep; 22 (1): 58–59. DOI: 10.1097/CND.0000000000000310.
23. Dinkin M, Gao V, Kahan J, et al. COVID‑19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology. 2020 Aug 4; 95 (5): 221–223. DOI: 10.1212/WNL.0000000000009700.
24. Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID‑19. Neurology. 2020 Aug 4; 95 (5): e601–e605. DOI: 10.1212/WNL.0000000000009619
Review
For citations:
Akhmedzhanova L.T., Zakharov V.V., Drozdova E.A., Dzhukkaeva S.A., Isaikin A.I., Voskresenskaya O.N., Surnina Z.V. Guillain-Barré syndrome associated with SARS-CoV‑2 (analysis of clinical cases). Medical alphabet. 2023;(2):22-28. (In Russ.) https://doi.org/10.33667/2078-531-2023-2-22-28
Views:
524
Email this article 